This hypothesis aligns well with recent findings highlighting the importance of effectively targeting HDAC3 to overcome resistance to pan-HDAC inhibitors in diffuse large B-cell lymphoma [54]. This evidence concerns the gene HDAC9 and diffuse large B-cell lymphoma.